|
rs1799793
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ERCC2-rs1799793-AA genotype correlated with ER+ and PR+ breast cancer.
|
29544444 |
2018 |
|
rs11615
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer.
|
27768589 |
2016 |
|
rs1800975
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer.
|
27768589 |
2016 |
|
rs2228001
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer.
|
27768589 |
2016 |
|
rs50872
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two polymorphisms (rs2228001 and rs50872) were associated with the risk of breast cancer with negative lymph node involvement. rs1800975 and rs50872 were associated with the risk of ER- and PR- breast cancer, whereas rs11615 was associated with the risk of ER+ and PR+ breast cancer.
|
27768589 |
2016 |
|
rs1408080623
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of this study was to evaluate the association of CYP2D6*10 (c.100C>T and c.1039C>T), OATP1B1 A388G, and OATP1B1 T521C polymorphisms with overall survival (OS) for hormone receptor (estrogen receptor or progesterone receptor)-positive tumors (ER+/PR+) breast cancer patients after adjuvant tamoxifen (TAM) therapy.
|
25701109 |
2015 |
|
rs4149056
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of this study was to evaluate the association of CYP2D6*10 (c.100C>T and c.1039C>T), OATP1B1 A388G, and OATP1B1 T521C polymorphisms with overall survival (OS) for hormone receptor (estrogen receptor or progesterone receptor)-positive tumors (ER+/PR+) breast cancer patients after adjuvant tamoxifen (TAM) therapy.
|
25701109 |
2015 |
|
rs10069690
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Index SNPs in five loci were replicated, including three associated with ER-/PR- breast cancer (TERT rs10069690 in 5p15.33, rs704010 in 10q22.3, and rs8170 in 19p13.11): per allele ORs were 1.29 [95% confidence interval (CI) 1.04-1.59], P = 0.02, 1.52 (95% CI 1.12-2.08), P = 0.01, and 1.30 (95% CI 1.01-1.68), P = 0.04, respectively.
|
23136140 |
2013 |
|
rs8170
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Index SNPs in five loci were replicated, including three associated with ER-/PR- breast cancer (TERT rs10069690 in 5p15.33, rs704010 in 10q22.3, and rs8170 in 19p13.11): per allele ORs were 1.29 [95% confidence interval (CI) 1.04-1.59], P = 0.02, 1.52 (95% CI 1.12-2.08), P = 0.01, and 1.30 (95% CI 1.01-1.68), P = 0.04, respectively.
|
23136140 |
2013 |
|
rs10941679
|
|
|
0.010 |
GeneticVariation |
BEFREE |
SNP 5p12-rs10941679 was statistically significantly associated with greater risk of progesterone receptor-positive than progesterone receptor-negative breast cancer (P(heterogeneity) = .0028).
|
21791674 |
2011 |
|
rs1008805
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among premenopausal women, the presence of at least one G allele at rs1008805 was significantly associated with an increase in the risk of breast cancer (OR = 1.72 [95% CI, 1.20-2.49]), especially with estrogen and progesterone receptor negative breast cancer (OR = 3.89 [1.74-8.70] and OR = 2.52 [1.26-5.05], respectively).
|
17975727 |
2008 |